-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OoEJoIPQNrtCvmcVeeuRGabYJ00fQHHqOM/1ewOHr83IdQe5bhKhsKc4o9ap39WF eCM1aGdQI1RVXPrJS9bl8Q== 0001144204-10-060866.txt : 20101115 0001144204-10-060866.hdr.sgml : 20101115 20101115164110 ACCESSION NUMBER: 0001144204-10-060866 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100930 FILED AS OF DATE: 20101115 DATE AS OF CHANGE: 20101115 EFFECTIVENESS DATE: 20101115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 101193124 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v201259_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: September 30, 2010 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. November 5, 2010 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 64 ----------- Form 13F Information Table Entry Value: $2,079,585 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 9-30-2010
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Achillion COM 00448Q201 4,448 1,472,697 SH SOLE 1,472,697 Acorda Therapeutics COM 00484M106 33,020 1,000,000 SH SOLE 1,000,000 Adolor Corp. COM 00724X102 7,699 7,128,659 SH SOLE 7,128,659 Alere Inc. COM 01449J105 57,142 1,847,463 SH SOLE 1,847,463 Allos Therapeutics Inc. COM 019777101 1,543 326,925 SH SOLE 326,925 Alsius Corp. COM 021211107 3 62,872 SH SOLE 62,872 Amicus Therapeutics COM 03152W109 4,102 1,046,499 SH SOLE 1,046,499 Amylin Pharmaceuticals COM 032346108 1,579 75,739 SH SOLE 75,739 Anadys Pharmaceuticals Inc. COM 03252Q408 560 241,302 SH SOLE 241,302 Anthera Pharmaceuticals COM 03674U102 3,352 800,000 SH SOLE 800,000 AP Pharma COM 00202J203 4,117 6,861,818 SH SOLE 6,861,818 Aradigm Corp. COM 038505301 19 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 129,872 5,646,589 SH SOLE 5,646,589 Autoimmune Inc. COM 052776101 6 13,050 SH SOLE 13,050 Auxilium COM 05334D107 147,721 5,961,306 SH SOLE 5,961,306 Avanir Pharmaceuticals COM 05348P401 1,595 500,000 SH SOLE 500,000 Biocryst Pharmaceuticals Inc. COM 09058V103 27,484 5,563,615 SH SOLE 5,563,615 Biomarin COM 09061G101 8,058 360,515 SH SOLE 360,515 Bristol Myers COM 110122108 1,084 40,000 SH SOLE 40,000 Cadence Pharmaceuticals COM 12738T100 4,983 596,818 SH SOLE 596,818 Chelsea Therapeutics COM 163428105 3,403 664,700 SH SOLE 664,700 Columbia Labs Inc. COM 197779101 1,200 1,111,112 SH SOLE 1,111,112 Cornerstone BioPharma COM 22674T105 793 112,337 SH SOLE 112,337 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 78 22,355 SH SOLE 22,355 Cumberland Pharmaceuticals COM 230770109 560 96,381 SH SOLE 96,381 Cypress Biosciences Inc. COM 232674507 1,155 300,000 SH SOLE 300,000 Dendreon Corp. COM 24823Q107 21,677 526,390 SH SOLE 526,390 Depomed COM 249908104 820 183,145 SH SOLE 183,145 Genomic Health Inc. COM 37244C101 89,661 6,711,184 SH SOLE 6,711,184 GTX Inc. COM 40052B108 1,832 532,660 SH SOLE 532,660 Halozyme Therapeutics Inc. COM 40637H109 26,181 3,395,667 SH SOLE 3,395,667 Human Genome COM 444903108 7,534 252,910 SH SOLE 252,910 Idera Pharmaceuticals Inc. COM 45168K108 949 288,401 SH SOLE 288,401 Incyte Corp. COM 45337C102 177,178 11,080,561 SH SOLE 11,080,561 Infinity Pharmaceuticals Inc. COM 45665G303 2,213 401,602 SH SOLE 401,602 Inhibitex Inc. COM 45719T103 1,570 872,303 SH SOLE 872,303 Inspire COM 457733103 11,900 2,000,000 SH SOLE 2,000,000 Intermune Inc. COM 45884X103 2,579 189,370 SH SOLE 189,370 Lexicon Pharmaceuticals COM 528872104 1,200 750,000 SH SOLE 750,000 Ligand Pharmaceuticals Inc. CLASS B 53220K207 793 501,697 SH SOLE 501,697 Medivation Inc. COM 58501N101 5,256 404,281 SH SOLE 404,281 Micromet COM 59509C105 27,719 4,124,911 SH SOLE 4,124,911 Neurogesx COM 641252101 1,235 178,681 SH SOLE 178,681 Pharmacyclics Inc. COM 716933106 5,176 640,578 SH SOLE 640,578 Pharmasset Inc. COM 71715N106 18,514 628,770 SH SOLE 628,770 Pharmathene COM 71714G102 492 323,807 SH SOLE 323,807 Salix Pharmaceuticals, Inc. COM 795435106 24,228 609,969 SH SOLE 609,969 Seattle Genetics Inc. COM 812578102 271,513 17,483,142 SH SOLE 17,483,142 Sucampo CLASS A 864909106 241 64,387 SH SOLE 64,387 Threshold Pharma COM 885807107 3,906 3,075,389 SH SOLE 3,075,389 Trimeris Inc. COM 896263100 8,758 3,475,475 SH SOLE 3,475,475 Via Pharmaceuticals COM 92554T103 10 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 155,989 10,462,071 SH SOLE 10,462,071 YM Biosciences COM 984238105 8,722 5,130,843 SH SOLE 5,130,843 Ziopharm Oncology Inc. COM 98973P101 3,919 1,045,000 SH SOLE 1,045,000 Zymogenetics COM 98985T109 14,954 1,533,774 SH SOLE 1,533,774 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 6,248 6,250,000 PRN SOLE 6,250,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 4,844 3,910,000 PRN SOLE 3,910,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 12,955 6,500,000 PRN SOLE 6,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 321,100 160,000,000 PRN SOLE 160,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 29,313 29,313,000 PRN SOLE 29,313,000 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 21,867 20,900,000 PRN SOLE 20,900,000 Salix 144A 5.5% 8/15/28 CONV BONDS 795435AB2 192,796 44,500,000 PRN SOLE 44,500,000 Salix 2.75% 5/15/15 CONV BONDS 795435AC0 148,167 130,400,000 PRN SOLE 130,400,000
-----END PRIVACY-ENHANCED MESSAGE-----